NEO — NEOGENOMICS INC
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1077183 ·
Last close
$16.02
Market Cap
$2.06B
52W High
$20.15
52W Low
$7.07
ADV30
2,333,196
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 201,656,000 | 91,878,000 | -9,771,000 | 2,238,000 | 1,352,243,000 | 145,539,000 | 566,511,000 |
| Mar 2026 | 186,672,000 | 80,864,000 | -18,241,000 | -17,106,000 | 1,346,531,000 | 146,143,000 | 517,771,000 |
| Dec 2025 | 190,170,000 | 83,343,000 | -12,788,000 | -9,881,000 | 1,359,830,000 | 159,618,000 | 523,268,000 |
| Sep 2025 | 187,797,000 | 80,446,000 | -19,928,000 | -27,129,000 | 1,374,780,000 | 164,117,000 | 536,490,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$22,049,000
Investing CF
$-19,901,000
Financing CF
$-11,386,000
CapEx
$-29,404,000
Dividends Paid
—
Buybacks
$-25,000,000
EPS Diluted TTM
$-0.40
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-448,674,000
Inventory
$27,137,000
Receivables
$175,405,000
ST Investments
$0
EBIT TTM
$-51,966,000
Pretax Income TTM
$-54,547,000
Interest Exp TTM
$2,581,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$766,294,976
EBITDA
$24,325,000
Free Cash Flow
$43,904,752
Enterprise Value
$2,528,023,552
Total Cash
$145,539,008
Total Debt
$448,368,000
Shares Out
128,475,440
Trailing EPS
$-0.39
Book Value
$6.14
ROE
-6.3%
ROA
-1.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 727,332,000 | -88,128,000 | -108,025,000 | 1,359,830,000 | 523,268,000 | 836,562,000 | 5,230,000 |
| Dec 2024 | 660,566,000 | -85,448,000 | -78,726,000 | 1,638,038,000 | 735,699,000 | 902,339,000 | 7,023,000 |
| Dec 2023 | 591,643,000 | -96,648,000 | -87,968,000 | 1,681,229,000 | 739,692,000 | 941,537,000 | -1,953,000 |
| Dec 2022 | 509,728,000 | -153,107,000 | -144,250,000 | 1,740,034,000 | 742,011,000 | 998,023,000 | -65,993,000 |
TTM Snapshot
Revenues TTM
$745,969,000
NetIncome TTM
$-99,208,000
OpCashFlow TTM
—
Assets (Latest)
$1,346,531,000
Forward EPS
$0.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BSTZ | BlackRock Science & Technology Term Trust | $2.06B | $29.91 | — |
| EVT | Eaton Vance Tax-Advantaged Dividend Income Fund | $2.07B | $27.72 | — |
| WLY | JOHN WILEY & SONS, INC. | $2.07B | $49.40 | — |
| PTON | PELOTON INTERACTIVE, INC. | $2.08B | $4.92 | — |
| EBOSY | EBOS Group Limited/ADR | $2.03B | $19.66 | — |
News headlines (Yahoo Finance, 1h cache)
Why NeoGenomics (NEO) Stock Is Up Today
2026-10-06 20:32 · Yahoo
Stryker, Neogenomics Announce CEO Transitions; Both Stocks Dive
2026-10-06 20:31 · Yahoo
NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
2026-10-06 17:09 · Yahoo
Did Strong Q3 Outlook and New CEO Plan Just Shift NeoGenomics' (NEO) Investment Narrative?
2026-10-06 17:08 · Yahoo
NeoGenomics stock falls on CEO transition announcement
2026-10-05 21:34 · Yahoo
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
2026-10-05 20:05 · Yahoo
3 Reasons NEO is Risky and 1 Stock to Buy Instead
2026-09-22 16:21 · Yahoo
NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?
2026-09-22 08:20 · Yahoo
Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?
2026-09-21 13:13 · Yahoo
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
2026-09-21 02:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.